A [new study](https://www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2020.201.1_MeetingAbstracts.A2928#aff8){#interrefs10} has concluded that adding selexipag to macitentan and tadalafil does not improve pulmonary vascular resistance in patients with pulmonary arterial hypertension (PAH). The results were presented at this year\'s American Thoracic Society International Conference, which was held online because of the COVID-19 pandemic.

The investigators randomly assigned 247 patients with PAH to receive first-line treatment either with macitentan and tadalafil, followed by the placebo at 15 days (n=124), or macitentan and tadalafil, followed by selexipag at 15 days (n=123). The patients had all been diagnosed with PAH in the 6 months before randomisation. Mean age was 52 years. The primary endpoint was change in pulmonary vascular resistance (PVR) at week 26. Secondary endpoints included change in 6-minute walk distance and time to disease progression.

There was no significant difference in change in PVR between the two groups. The patients given double combination therapy saw an improvement in PVR of 52%, relative to baseline levels, whereas those assigned the triple combination saw an improvement of 54%. "The results were fairly consistent across subgroups", said Kelly Chin (University of Texas Southwestern Medical Center, Dallas, TX, USA), the study\'s corresponding author. Secondary endpoints were also similar.

"This study addresses a pressing question in the field: does up-front triple therapy improve PVR compared with up-front dual therapy in PAH?", commented Bradley Maron (Harvard Medical School, Boston, MA, USA). "It appears this may not be the case with this particular approach. That is not the end of the story. There may be space to reconsider patient selection for up-front triple therapy, and we will also need to think about integrating the forthcoming molecular targeted therapies with the conventional therapies we already have." He cautioned against focusing exclusively on drugs. "We have very good data on the benefits of prescribed physical activity and exercise in PAH; it would be unfortunate if these options were overlooked", Maron told *The Lancet Respiratory Medicine*.

Chin points out that definitive answers on the benefits of pharmacotherapy in PAH can only be provided by studies that examine clinically important outcomes, such as survival. "The problem is that these kind of studies are very large and very expensive", she said. "But they are really important and the pulmonary hypertension community needs to figure out a way to make them happen."
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